Viatris and idorsia enter into significant global research and development collaboration

Expands viatris' portfolio of innovative assets by immediately adding two phase 3 assets, selatogrel and cenerimod, both with blockbuster revenue potential includes future optionality to expand collaboration with additional innovative assets combines viatris' financial strength and worldwide operational infrastructure with idorsia's proven, highly productive drug development team and innovation engine deal structure reinforces viatris' disciplined approach to capital allocation viatris announces r&d event to be held march 27, 2024 pittsburgh, feb. 28, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, and idorsia ltd (six: idia) today announced they have entered into agreements for a significant global research and development collaboration under which viatris will receive exclusive global development and commercialization rights to two phase 3 assets as well as the potential to add additional innovative assets in the future. the collaboration includes selatogrel, a potential life-saving self-administered medicine for patients with a history of acute myocardial infarction (ami), or heart attack, and builds on viatris' existing global cardiovascular franchise and specialty infrastructure, as well as its knowledge, leadership, and distribution capabilities for self-administered medication for acute life-threatening conditions.
VTRS Ratings Summary
VTRS Quant Ranking